DACXI® is part of the therapeutic class known as antithrombotic agents, whose action prevents the formation of thrombi. DACXI® is indicated for Prevention of stroke and clot formation in other blood vessels (systemic embolism); Treatment and prevention of deep vein thrombosis; Treatment and prevention of pulmonary embolism; Treatment and prevention of thromboembolism.
Rivaroxaban prevents the formation of blood clots inside blood vessels by inhibiting coagulation factor Xa, the agent responsible for clot formation by amplifying coagulation. DACXI® has different inactivation pathways for factor Xa
DACXI® comes in the following presentations: 10mg (30 tablets), 15mg (28 tablets) and 20mg (28 tablets).
Coated tablet
Antithrombotics
Sale on prescription